Pfizer Inc. (NYSE:PFE) Stock Position Decreased by Winslow Asset Management Inc.

Winslow Asset Management Inc. decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 10.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,197 shares of the biopharmaceutical company’s stock after selling 981 shares during the quarter. Winslow Asset Management Inc.’s holdings in Pfizer were worth $237,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. acquired a new position in shares of Pfizer during the first quarter valued at $315,000. GSA Capital Partners LLP acquired a new stake in shares of Pfizer in the first quarter valued at approximately $439,000. Cozad Asset Management Inc. raised its holdings in shares of Pfizer by 12.9% during the first quarter. Cozad Asset Management Inc. now owns 43,837 shares of the biopharmaceutical company’s stock valued at $1,216,000 after buying an additional 5,005 shares during the last quarter. Koshinski Asset Management Inc. grew its holdings in Pfizer by 20.5% in the 1st quarter. Koshinski Asset Management Inc. now owns 24,265 shares of the biopharmaceutical company’s stock worth $673,000 after buying an additional 4,130 shares in the last quarter. Finally, WP Advisors LLC increased its position in Pfizer by 53.9% in the 1st quarter. WP Advisors LLC now owns 65,241 shares of the biopharmaceutical company’s stock valued at $1,810,000 after acquiring an additional 22,844 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of the company’s stock in a transaction dated Wednesday, October 30th. The shares were bought at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on PFE shares. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research note on Wednesday, October 9th. Barclays boosted their price target on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Citigroup began coverage on shares of Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price objective for the company. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Eight investment analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $33.58.

Pfizer Trading Down 1.8 %

NYSE:PFE opened at $26.24 on Tuesday. The stock has a fifty day simple moving average of $28.84 and a 200 day simple moving average of $28.67. The company has a quick ratio of 0.60, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $148.70 billion, a price-to-earnings ratio of 35.46, a price-to-earnings-growth ratio of 0.85 and a beta of 0.67. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. During the same quarter in the prior year, the firm earned ($0.17) EPS. The firm’s quarterly revenue was up 31.2% on a year-over-year basis. Sell-side analysts forecast that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.40%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio is currently 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.